


# Product Data Sheet

## WP1130

<b>Cat. No.:</b>	A8323
<b>CAS No.:</b>	856243-80-6
<b>Formula:</b>	C <sub>19</sub> H <sub>18</sub> BrN <sub>3</sub> O
<b>M.Wt:</b>	384.27
<b>Synonyms:</b>	WP 1130; WP-1130
<b>Target:</b>	Ubiquitination/ Proteasome
<b>Pathway:</b>	DUB
<b>Storage:</b>	Store at -20°C



## Solvent & Solubility

≥38.4 mg/mL in DMSO; insoluble in H<sub>2</sub>O; ≥7.23 mg/mL in EtOH

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	<b>Concentration</b>			
	<b>1 mM</b>	2.6023 mL	13.0117 mL	26.0234 mL
	<b>5 mM</b>	0.5205 mL	2.6023 mL	5.2047 mL
	<b>10 mM</b>	0.2602 mL	1.3012 mL	2.6023 mL

Please refer to the solubility information to select the appropriate solvent.

## Biological Activity

Shortsummary

Deubiquitinase (DUB) inhibitor, Cell permeable

IC<sub>50</sub> & Target

(DUB), 1.8 μM (Bcr-Abl)

In Vitro

### Cell Viability Assay

Cell Line:	The human typical MCL cell lines (Mino, DB, Z-138, and JMP-1)
Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	48 h; EC <sub>50</sub> ≈~1 μM

	Applications:	Degrasyn (WP1130) had superior inhibitory activity in the JAK/STAT pathway and the antiproliferative effect. These studies showed that cell growth suppression was seen in all three compounds (WP1130, WP1129 and WP1066) for all four cell lines, and the half maximal effective concentration (EC50) of Degrasyn was lower than that of the other two compounds in all four MCL cell lines, suggesting that Degrasyn is a more effective anti-tumor agent in MCL cells.
In Vivo	<b>Animal experiment</b>	
	Animal models:	Young SCID mice
	Dosage form:	20 mg/kg; i.p.
	Applications:	Using a xenotransplant SCID mouse model of MCL. Degrasyn alone showed modest prolongation of survival compared with vehicle alone ( $P < 0.105$ ). In addition, normal control mice ( $n = 5$ ) given treatment with Degrasyn alone or in combination with bortezomib remained alive and showed no signs of body weight loss.
	Other notes:	Please test the solubility of all compounds in vivo, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

1. Narayanan N, Wang Z, et al. "Arginine methylation of USP9X promotes its interaction with TDRD3 and its anti-apoptotic activities in breast cancer cells." *Cell Discov.* 2017 Jan 3;3:16048. PMID:28101374

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1] Pham L V, Tamayo A T, Li C, et al. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications [J]. *Molecular cancer therapeutics*, 2010, 9(7): 2026-2036.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

